Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth

Molecular Cancer Therapeutics

Volumn 12, Issue 10, 2013, Pages 1935-1946

  Büll, Christian ^a   Boltje, Thomas J ^b   Wassink, Melissa ^a   De Graaf, Annemarie M A ^a   Van Delft, Floris L ^b   Den Brok, Martijn H ^a   Adema, Gosse J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; COLLAGEN TYPE 1; FIBRONECTIN; FLUORINE; MANNOSAMINE; N ACETYLNEURAMINIC ACID DERIVATIVE; POLYLYSINE; SIALIC ACID DERIVATIVE; SIALYLTRANSFERASE;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN BF16F10; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME SUBSTRATE; FEMALE; FLUORINATION; GLIOBLASTOMA; MELANOMA B16; METASTASIS; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIALYLATION; SURVIVAL TIME;

ANIMALS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; FLUORINE; HUMANS; MELANOMA, EXPERIMENTAL; MICE; N-ACETYLNEURAMINIC ACID; POLYSACCHARIDES; SIALIC ACIDS;

EID: 84885637740     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0279     Document Type: Article

References (48)

1. Sakuma K, Aoki M, Kannagi R. Transcription factors c-Myc and CDX2 mediate E-selectin ligand expression in colon cancer cells undergoing EGF/bFGF-induced epithelial-mesenchymal transition. Proc Natl Acad Sci U S A 2012;109: 7776-81.
2. Maupin KA, Sinha A, Eugster E, Miller J, Ross J, Paulino V, et al. Glycogene expression alterations associated with pancreatic cancer epithelial-mesenchymal transition in complementary model systems. PLoS ONE 2010;5:e13002.
3. Dalziel M, Dall'Olio F,Mungul A, Piller V, Piller F. Ras oncogene induces beta-galactoside alpha2,6-sialyltransferase (ST6Gal I) via a RalGEFmediated signal to its housekeeping promoter. Eur J Biochem 2004; 271: 3623-34.
4. Swindall AF, Bellis SL. Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. J Biol Chem 2011;286: 22982-90.
5. Amano M, Eriksson H, Manning JC, Detjen KM, Andre S, Nishimura S, et al. Tumour suppressor p16(INK4a) - anoikis-favouring decrease in N/O-glycan/cell surface sialylation by down-regulation of enzymes in sialic acid biosynthesis in tandem in a pancreatic carcinoma model. FEBS J 2012;279: 4062-80.
6. Cui H, Lin Y, Yue L, Zhao X, Liu J. Differential expression of the alpha2,3-sialic acid residues in breast cancer is associated with metastatic potential. Oncol Rep 2011;25: 1365-71.
7. Lee M, Lee HJ, Bae S, Lee YS. Protein sialylation by sialyltransferase involves radiation resistance. Mol Cancer Res 2008;6: 1316-25.
8. Park JJ, Yi JY, Jin YB, Lee YJ, Lee JS, Lee YS, et al. Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells. Biochem Pharmacol 2012;83: 849-57.
9. Chang WW, Yu CY, Lin TW, Wang PH, Tsai YC. Soyasaponin I decreases the expression of alpha2,3-linked sialic acid on the cell surface and suppresses the metastatic potential of B16F10 melanoma cells. Biochem Biophys Res Commun 2006;341: 614-9.
10. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005;5: 526-42.
11. Lu DY, Lu TR, Wu HY. Development of antimetastatic drugs by targeting tumor sialic acids. Sci Pharm 2012;80: 497-508.
12. Hosoguchi K, Maeda T, Furukawa J, Shinohara Y, Hinou H, Sekiguchi M, et al. An efficient approach to the discovery of potent inhibitors against glycosyltransferases. J Med Chem 2010;53: 5607-19.
13. Varki A, Schauer R. Sialic acids. In:Varki A, Cummings RD, Esko JD, et al., eds. Essentials of glycobiology. 2nd ed. New York, NY: Cold Spring Harbor; 2009.
14. Harduin-Lepers A, Mollicone R, Delannoy P, Oriol R. The animal sialyltransferases and sialyltransferase-related genes: a phylogenetic approach. Glycobiology 2005;15: 805-17.
15. Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y, et al. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res 1993;53: 3632-7.
16. Hedlund M, Ng E, Varki A, Varki NM. Alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. Cancer Res 2008;68: 388-94.
17. Tanaka F, Otake Y, Nakagawa T, Kawano Y, Miyahara R, Li M, et al. Expression of polysialic acid and STX, a human polysialyltransferase, is correlated with tumor progression in non-small cell lung cancer. Cancer Res 2000;60: 3072-80.
18. Schultz MJ, Swindall AF, Bellis SL. Regulation of the metastatic cell phenotype by sialylated glycans. Cancer Metastasis Rev 2012;31: 501-18.
19. Picco G, Julien S, Brockhausen I, Beatson R, Antonopoulos A, Haslam S, et al. Over-expression of ST3Gal-I promotes mammary tumorigenesis. Glycobiology 2010;20: 1241-50.
20. Seales EC, Jurado GA, Brunson BA, Wakefield JK, Frost AR, Bellis SL. Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res 2005;65: 4645-52.
21. Perez-Garay M, Arteta B, Pages L, de Llorens R, de Bolos C, Vidal-Vanaclocha F, et al. alpha2,3-sialyltransferase ST3Gal III modulates pancreatic cancer cell motility and adhesion in vitro and enhances its metastatic potential in vivo. PLoS ONE 2010;5: pii: e12524.
22. Rillahan CD, Antonopoulos A, Lefort CT, Sonon R, Azadi P, Ley K, et al. Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. Nat Chem Biol 2012;8: 661-8.
23. Munster AK, Weinhold B, Gotza B, Muhlenhoff M, Frosch M, Gerardy-Schahn R. Nuclear localization signal of murine CMP-Neu5Ac synthetase includes residues required for both nuclear targeting and enzymatic activity. J Biol Chem 2002;277: 19688-96.
24. Eckhardt M, Muhlenhoff M, Bethe A, Gerardy-Schahn R. Expression cloning of the Golgi CMP-sialic acid transporter. Proc Natl Acad Sci U S A 1996;93: 7572-6.
25. Chiaramonte M, Koviach JL, Moore C, Iyer VV, Wagner CR, Halcomb RL, et al. Inhibition of CMP-sialic acid transport into Golgi vesicles by nucleoside monophosphates. Biochemistry 2001;40: 14260-7.
26. Martinez J, Nguyen LD, Hinderlich S, Zimmer R, Tauberger E, Reutter W, et al. Crystal structures of N-acetylmannosamine kinase provide insights into enzyme activity and inhibition. J Biol Chem 2012;287: 13656-65.
27. Hinderlich S, Stasche R, Zeitler R, Reutter W. A bifunctional enzyme catalyzes the first two steps in N-acetylneuraminic acid biosynthesis of rat liver. Purification and characterization of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase. J Biol Chem 1997; 272: 24313-8.
28. Burkart MD, Zhang ZY, Hung SC, Wong CH. A new method for the synthesis of fluoro-carbohydrates and glycosides using selectfluor. J Am Chem Soc 1997;119: 11743-6.
29. Kroesen M, Nierkens S, Ansems M, Wassink M, Orentas RJ, Boon L, et al. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma. Int J Cancer. Epub 2013 Sept 14.
30. Hillrichs K, Schnieder T, Forbes AB, Simcock DC, Pedley KC, Simpson HV. Use of fluorescent lectin binding to distinguish Teladorsagia circumcincta and Haemonchus contortus eggs, third-stage larvae and adult worms. Parasitol Res 2012;110: 449-58.
31. Angeloni S, Ridet JL, Kusy N, Gao H, Crevoisier F, Guinchard S, et al. Glycoprofiling with micro-arrays of glycoconjugates and lectins. Glycobiology 2005;15: 31-41.
32. Wearne KA, Winter HC, O'Shea K, Goldstein IJ. Use of lectins for probing differentiated human embryonic stem cells for carbohydrates. Glycobiology 2006;16: 981-90.
33. Batisse C, Marquet J, Greffard A, Fleury-Feith J, Jaurand MC, Pilatte Y. Lectin-based three-color flow cytometric approach for studying cell surface glycosylation changes that occur during apoptosis. Cytometry A 2004;62: 81-8.
34. Keppler OT, Hinderlich S, Langner J, Schwartz-Albiez R, Reutter W, Pawlita M. UDP-GlcNAc 2-epimerase: a regulator of cell surface sialylation. Science 1999;284: 1372-6.
35. Matsumoto A, Cabral H, Sato N, Kataoka K, Miyahara Y. Assessment of tumor metastasis by the direct determination of cell-membrane sialic acid expression. Angew Chem Int Ed Engl 2010;49: 5494-7.
36. den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Toonen LW, Figdor CG, et al. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res 2006;66: 7285-92.
37. Yogeeswaran G, Salk PL. Metastatic potential is positively correlated with cell surface sialylation of cultured murine tumor cell lines. Science 1981;212: 1514-6.
38. Peters BP, Ebisu S, Goldstein IJ, Flashner M. Interaction of wheat germ agglutinin with sialic acid. Biochemistry 1979;18: 5505-11.
39. Warren L, Felsenfeld H. The biosynthesis of sialic acids. J Biol Chem 1962;237: 1421-31.
40. Corfield AP, Higa H, Paulson JC, Schauer R. The specificity of viral and bacterial sialidases for alpha(2-3)- and alpha(2-6)-linked sialic acids in glycoproteins. Biochim Biophys Acta 1983;744: 121-6.
41. Almaraz RT, Tian Y, Bhattarcharya R, Tan E, Chen SH, Dallas MR, et al. Metabolic flux increases glycoprotein sialylation: implications for cell adhesion and cancer metastasis. Mol Cell Proteomics 2012;11:M112 017558.
42. Du J, Meledeo MA, Wang Z, Khanna HS, Paruchuri VD, Yarema KJ. Metabolic glycoengineering: sialic acid and beyond. Glycobiology 2009;19: 1382-401.
43. Veiga SS, Chammas R, Cella N, Brentani RR. Glycosylation of beta-1 integrins in B16-F10 mouse melanoma cells as determinant of differential binding and acquisition of biological activity. Int J Cancer 1995;61: 420-4.
44. Semel AC, Seales EC, Singhal A, Eklund EA, Colley KJ, Bellis SL. Hyposialylation of integrins stimulates the activity of myeloid fibronectin receptors. J Biol Chem 2002;277: 32830-6.
45. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012;196: 395-406.
46. Eckhardt M, Gotza B, Gerardy-Schahn R. Mutants of the CMP-sialic acid transporter causing the Lec2 phenotype. J Biol Chem 1998; 273: 20189-95.
47. Seales EC, Shaikh FM, Woodard-Grice AV, Aggarwal P, McBrayer AC, Hennessy KM, et al. A protein kinase C/Ras/ERK signaling pathway activates myeloid fibronectin receptors by altering beta1 integrin sialylation. J Biol Chem 2005;280: 37610-5.
48. Seales EC, Jurado GA, Singhal A, Bellis SL. Ras oncogene directs expression of a differentially sialylated, functionally altered beta1 integrin. Oncogene 2003;22: 7137-45.